Heart failure with preserved ejection fraction
Conditions
Interventions
Administration of ivabradine
Sponsors
Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with heart failure with preserved ejection fraction including Stage A heart failure (2) Patients with resting heart rate greater than equal to 75bpm (3) NYHA functional classification and receiving cardio-protective drugs such as ACE inhibitors, ARBs, or beta-blockers has been stable for 4 weeks from enrollment
Exclusion criteria
Exclusion criteria: (1) Patients with atrial fibrillation (2) Patients with sick sinus syndrome, interatrial block, third-degree atrioventricular block (3) Patients with hypotension (systolic blood pressure less than 90mmHg or diastolic blood pressure less than 50mmHg) (4) Patients with severe liver disease (Child-Pugh C) (4) Patients with hyperkalemia or serum potassium level>5.0mEq/L at enrollment (5) Patients erceiving Ritonavir pharmacokinetics, Josamycin, Itraconazole, Clarithromycin, Cobicistat, Indinavir, Voriconazole, Nelfinavir mesilate, Saquinavir, Telaprevir, Verapamil hydrochloride,Diltiazem hydrochloride (6) Pregnant women, lactating woman or women who wish to a pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A change in E/e' between baseline and 6 months after the start of administration of ivabradine | — |
Secondary
| Measure | Time frame |
|---|---|
| A change in BNP (NT-proBNP) and left atrial volume index between baseline and 6 months after the start of administration of ivabradine | — |
Countries
Japan
Contacts
Public ContactHidekazu Tanaka
Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine
Outcome results
None listed